A Study of LY3561774 in Participants With Dyslipidemia

Summary

This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high blood fat levels). How the body processes the study drug and the effect of the study drug on blood fat levels will also be investigated. Part C will mainly evaluate the safety and tolerability of LY3561774 as well as how the body processes the study drug in Japanese participants. The study may last up 52, 56 and 28 weeks for each participant in Parts A, B and C, respectively. There are up to 22, 26 and 16 visits in Parts A, B and C, respectively.

Timeline

Start

2020-11-30

Primary completion

2022-05-17

Completion

2022-05-17

Publications

• Ray KK, Linnebjerg H, Michael LF, Shen X, Ma X, Lim S, Zhen EY, Dudek H, Abrams M, Saxena U, Turanov A, Nicholls SJ, Ruotolo G. Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies. J Am Coll Cardiol. 2025 May 20;85(19):1803-1818. doi: 10.1016/j.jacc.2025.03.005. Epub 2025 Mar 30.

Drugs

Indications